Combination treatment for advanced gastric cancer with HER2 overexpression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of a combination treatment involving Disitamab Vedotin, Tislelizumab, and Capecitabine for patients with locally advanced gastric cancer or gastroesophageal junction adenocarcinoma that overexpresses HER2. A total of 40 patients who have not received prior anti-tumor therapy will undergo perioperative treatment, which includes both neoadjuvant and adjuvant phases. The neoadjuvant phase consists of 3 cycles of treatment, followed by 5 cycles in the adjuvant phase, with the aim of improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Volunteer to take part in the study ;
* 2\) Age 18\~75 (including 75), male or female;
* 3\) Gastric cancer or adenocarcinoma of gastroesophageal junction confirmed by histology and/or cytology;
* 4\) Clinical stage Ⅱ, Ⅲ (cT2-4a ,N+ or -, M0, AJCC 8th);
* 5\) Have not received systematic treatment;
* 6\) The HER2 immunohistochemistry (IHC) test result is IHC 3+or 2+, and the previous test results of the subject (confirmed by the investigator) are acceptable;
* 7\) At least one assessable lesion (RECIST 1.1 );
* 8\) Expected survival time ≥ 6 months;
* 9\) ECOG 0-1;
* 10\) Major organs are functioning normally；

Exclusion Criteria:

* 1\) Have a history of malignant tumors other than gastric cancer, except for the following two cases:

  1. The patient has received possible curative treatment and there is no evidence of the disease within 5 years;
  2. The resected skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ and other carcinoma in situ were successfully received;
* 2\) Suffering from diseases that affect the absorption, distribution, metabolism or clearance of the study drug (such as severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorder, etc.);
* 3\) Have received allogeneic stem cells or solid organ transplantation in the past;
* 4\) Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation);
* 5\) Previous or current congenital or acquired immunodeficiency disease;
* 6\) Active or previously recorded autoimmune diseases or inflammatory diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, hypophysitis, hyperthyroidism or hypothyroidism, asthma requiring bronchodilators, etc.), vitiligo or asthma that has completely alleviated in childhood, Those who do not need any intervention after adulthood can be included;
* 7\) Systemic immunosuppressive drugs were used within 2 weeks before enrollment, or were expected to be required during the study, except for the following:

  1. Corticosteroids for intranasal, inhalation, external or local injection (such as intra-articular injection);
  2. The dose of prednisone or other equivalent systemic corticosteroids does not exceed 10 mg/day;
  3. Preventive use of corticosteroids for hypersensitivity;
* 8\) Allergic to the study drug;
* 9\) Thrombosis or thromboembolism events occurred in the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc;
* 10\) Patients at risk for severe bleeding；
* 11\) Cardiovascular diseases with significant clinical significance;
* 12\) Other significant clinical and laboratory abnormalities, which the researchers think affect the safety evaluation;
* 13\) Serious infection in active period or poorly controlled clinically;
* 14\) Not recovered from the operation;
* 15\) Pregnant or lactating women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures;
* 16\) Other situations that the investigator thinks are not suitable for inclusion.

Where it's running

• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, Tianjin Municipality, China Recruiting
• Xuewei Ding
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Han Liang, Ph.D — Tianjin Medical University Cancer Institute and Hospital
• Study coordinator: Xuewei Ding, Ph.D
• Email: xding@tmu.edu.cn
• Phone: 18622220158

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Disitamab Vedotin and Cadonilimab for HER2-expressing Gastric Cancer

  This study is testing if combining two treatments, Disitamab Vedotin and Cadonilimab, can help people with advanced gastric cancer that has not responded to earlier treatments.

  Recruiting at 5 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT06221748

• Combination therapy for advanced gastric cancer

  This study is testing a new combination treatment for advanced gastric cancer to see if it works better than the usual options for patients with a specific type of the disease.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT06155383

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• BL-M05D1 vs investigator's choice in CLDN 18.2-positive advanced gastric/GEJ cancer

  This phase 3 study tests BL-M05D1 against the treating physician’s chosen therapy in adults with CLDN 18.2-positive advanced gastric or GEJ cancer after first-line treatment.

  Recruiting Phase 3 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07518147

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.